TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Discontinuation of treatment due to TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Maternal Gestational Weight Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Infant Weight-for-Length Z-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects With Anti-gE Antibody Concentrations Equal to or Above the Cut-off Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relieve of Anal Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Successfully Acquired 89Zr-bevacizumab-PET/CT scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Person With Dementia Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: proportion of patients with OT and/or PT consultations by ICU
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: time mobilization activities performed in the ICU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perme intensive care unit mobility score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relief of OA signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Have a Clinical Response to Treatment (Objective Tumor Regression)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Adverse Events With Grades ≥1 That Are Possibly, Probably, and/or Definitely Related to Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Inhaler counter advancement without actuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SUV of organs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radioactivity of blood sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SUV of glioma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: SUV of Breast Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in the metabolomics profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biochemically validated quit rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Arm (FMA) Motor Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hard tissue gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Assessment Questionnaire (HAQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Day of neutrophil engraftment (ANC>0.5x10^9/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Day of platelet engraftment (>25x10^9/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: nycthemeral intraocular pressure patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Proportion of patients achieving a total reduction of at least 2 grades in the IGA scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathological Gambling Adaptation of Yale-Brown Obsessive Compulsive Scale (PG-YBOCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diurnal change in serum magnesium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving SLE Responder Index (SRI)-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of pregnant women
Endpoint domain: Mortality/survival
Primary endpoint: Fordyce Happiness Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Peak Systolic Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak Diastolic Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak Temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with hypoxia (PaO2< 90mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in breast pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Improvement in patient function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Achieving Serotype-specific IgG Antibody Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Reporting Any Local and Systemic Solicited Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Medically Attended AEs (MAAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Reporting Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of Ketorolac in peritoneal cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for Children's Palliative Care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Side branch occlusion
Endpoint domain: Adverse events/effects
Primary endpoint: 3-month cessation rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mortality of CVT
Endpoint domain: Mortality/survival
Primary endpoint: Change from Baseline of Glucose Turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline of homeostatic model assessment (HOMA) for insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline of beta cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Coefficient of variation of relative quantities of metabolites and physiological parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iron micronutrient levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of adverse outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: daily insulin requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Human airway reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: length of gestation
Endpoint domain: Mortality/survival
Primary endpoint: complete healing of fissure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loss of anal continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Four-week continuous quit rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number or percentage of relevant OHRQoL issues addressed
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: patient's participation between the intervention and control groups
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: 9-item Consultation Satisfaction Questionnaire (CSQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Compliance rate with ONS
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficiency of eye movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-monitoring blood glucose (SMBG) value at 6 hours after meals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subjective Bilateral Pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline in the Scale for Assessment of Negative Symptoms (SANS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Microvascular Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean area under the curve (AUC) 0-6h in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean terminal half-life (t1/2) in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Respiratory Viral Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Geometric Mean Fold Change From Baseline in Varicella Zoster Virus (VZV)-Specific Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Reporting an Adverse Experience (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting a Serious Adverse Experience (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Differences in ERG components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects who are pain free at 2 hrs post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: renal response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: proportion of patients spared hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from Baseline in Clinician-administered ADHD-5-Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retrieval Session Distress Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Retrieval Session Craving Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Test Session Distress Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Test Session Craving Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Drug levels of lamotrigine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TEMPS-A scale measurement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PUQE scoring index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of standardized uptake value of 68Ga-DOTA-TATE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of 3.7GBq of 177Lu-DOTA-EB-TATE
Endpoint domain: Adverse events/effects
Primary endpoint: evening settling difficulties
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: muscle strength of upper limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: groin wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Cessation Success at Week 10 After Target Quit Date
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number Moderate or Severe Side Effects
Endpoint domain: Adverse events/effects
Primary endpoint: Birth Outcomes for Gestational Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Frontal Plane Rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fMRI BOLD response in the amygdala and insula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: State-anxiety inventory (STAI-S)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in systolic arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression of healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of CSF drainage
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of CSF drainage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-cell immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of lost to follow-up patients successfully re-linked to care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of subjects with confirmed Zika, Chikungunya, or Dengue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: proportion surviving
Endpoint domain: Mortality/survival
Primary endpoint: Formation of Pressure Ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in expression of key allergy targets in the nose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Healing of chronic diabetic ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants Having Unprotected Casual Sex
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Global health and functional scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: C30 symptom scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: CR29 scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cirrhosis dysbiosis ratio (CDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adverse Events and DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in insulin resistance via HOMA-IR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Doppler signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of subclinical myocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Assessment of coronary blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correlation between cardiac abnormalities and disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: WOMAC Pain sub-score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Plasma AUC(0-t), AUC(0-inf), Cmax, tmax, and t1/2 of GSK945237
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount excreted in urine (Ae) and renal clearance of GSK945237
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: prevalence of gestational diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: prevalence of gestational hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of cesarean section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: neonatal weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neonatal height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 11C-Altropane Binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Behavioral Performance in Probabilistic Reward Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Brain Activity during Instrumental Learning Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Behavioral Performance in Instrumental Learning Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Behavioral Performance in the Social Reinforcement Learning Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum Tolerated Dose (MTD) of pioglitazone and carboplatin
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative Incidence of New Symptomatic Thromboembolic Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diabetes Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of grade III/IV neutropenia in the first cycle
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of grade III/IV neutropenia in the second cycle
Endpoint domain: Adverse events/effects
Primary endpoint: Time to establish dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Eating Disorder Examination (EDE)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Inhibition of the P2Y12 Receptor as Measured by Platelet Reaction Unit (PRU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in average blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycated Albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Viral Load-time Curve (VL AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: structure of sarcolemma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of vaccination against influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain thresholds and tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Triglyceride/HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Perceived Social Support
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Complications according to clavien system
Endpoint domain: Adverse events/effects
Primary endpoint: Change in STP as assessed by Numeric Rating Scale (NRS-11)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the occurrence of first stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Total defecation time (duration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Arrhythmia detection accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Oxygen cost of isolated muscle contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue time during muscle group specific contractile activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Fatigue
Primary endpoint: Change in postprandial glucose regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients With Physician's Global Assessment (sPGA) Score 0 or 1
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: differences in fecal microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Response rate (best overall response under treatment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Recurrence (TTR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Program feasibility and fidelity
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: safety and efficacy of multiple cord blood transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of bacterial peritonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Global Response Assessment (GRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in myocardial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: All cause adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Magnitude of inspiratory premotor potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Timed up and go test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ashworth Scale results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Rivermeade Motor Assessment (RMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in REPTY questionnaire results
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Tight Circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detectability of lung and liver lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful Outcome According to Investigator's Global Assessment (IGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Inflammatory Acne Lesion Count on the Face at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Neurocognitive impairments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: hypnotic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes